TY  - JOUR
T1  - The Role of DPP-4 Inhibitors in Cardiovascular Protection among Type-2 Diabetic Patients; Literature Review
A1  - Khaled Naif Alduaig
A1  - Osama Khalid Alzahrani
A1  - Asaad Abdellahi Bilal
A1  - Ibrahim Saleh Al Hutaylah
A1  - Saud Hussain Alhelal
A1  - Sukinah Makki Almuslim
A1  - Duaa Jawad Aljumah
A1  - Khadijah Hassan Muzaffar
A1  - Khalid Ibrahim Aseeri
A1  - Reem Hady Hrooby
JF  - Archives of Pharmacy Practice
JO  - Arch Pharm Pract
SN  - 2320-5210
Y1  - 2021
VL  - 12
IS  - 3
DO  - 10.51847/qKsetZesUV
SP  - 113
EP  - 116
N2  - A combination of metabolic disorders manifested by increased blood glucose levels causes Diabetes mellitus. Patients with diabetes are more prone to morbidity and increased rate of mortality compared to the general population, with a substantial contribution to healthcare costs. One of the significant risk factors for cardiovascular problems is Diabetes Mellitus. Hence, the additional cardiovascular beneficial effect has been reported in various new antidiabetic agents, including DPP-4 inhibitors. This literature aims to evaluate the cardiovascular efficacy and safety of DPP-4 inhibitors. We used PubMed search engine to search for relevant studies. We used different Mesh words, including "DPP-4, Diabetes mellitus, cardiovascular risk, heart failure". DPP-4 inhibitors may provide cardiovascular benefit amount type-2 diabetic patients. There is still debate about the increased risk of heart failure hospitalization. Generally, DPP-4 inhibitors are secure, and endure and accepted by the patients. It should be noted that a beneficial atherosclerotic effect was reported with inhibitors of DPP-4. However, the HF hospitalization risk remains an area of debate. Further multi-national trials are recommended to establish DPP-4 inhibitors' cardiovascular efficacy safety.
UR  - https://archivepp.com/article/the-role-of-dpp-4-inhibitors-in-cardiovascular-protection-among-type-2-diabetic-patients-literature-z0d9tqkjesuip4m
ER  -